Skip to Main Content

Try STAT+ TODAY

government agencies

Most Read

low-dose radiation

First Opinion By Joe Gray, Lindsay Morton and Gayle Woloschak

The U.S. needs to revitalize research on the health effects of low-dose radiation

a photo of the federal trade comission building

Hospitals By Bob Herman

HCA, Steward abandon hospital deal in another win for FTC

vaccines booster

Health By Matthew Herper

FDA authorizes Pfizer and Moderna Covid vaccines for infants, toddlers, and preschoolers

patient safety

First Opinion By Christi A. Grimm, Ruth Ann Dorrill and Julie K. Taitsman

New report: gains in patient safety have stalled over the past decade

FDA sign FDA commissioner

Pharmalot By Ed Silverman

FDA oversight of pharma manufacturing facilities plunges during the pandemic

Hospitals By Tara Bannow

The FTC says it’s getting tougher on hospital consolidation. Antitrust experts aren’t buying it

FDAApprovalPt2_Illustration_MollyFerguson_041222

Pharmalot By Ed Silverman

Quantity over quality: FDA approved more cancer drugs than EMA, but they may not have always benefited patients

Biotech By Damian Garde

FDA advisers unanimously endorse Bluebird’s gene therapy for rare disorder

All Coverage

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Juul’s doomsday, Merck’s buyout plans, & the next Theranos verdict

Food And Drug Administration Headquarters 2020 fda hearing

Politics By Nicholas Florko

Despite fanfare, the FDA’s step toward lowering nicotine levels in cigarettes is a very early one

advertisement

Politics By Lev Facher

Biden picks former DARPA director Prabhakar as next science adviser

Patent folder IP nationalism

Pharmalot By Ed Silverman

Senate lawmakers introduce a bill to help the FDA and the U.S. Patent Office coordinate

Pharmalot By Ed Silverman

Pharmalittle: Lawmakers urge FTC to probe blood thinner prices; EU pressures Covid vaccine makers to renegotiate contracts

Father and baby imprinting

First Opinion By Steve Brozak and Richard Marfuggi

Lessons from earlier pandemics: Vaccine panel must discuss imprinting among infants and toddlers

Pharmalot By Ed Silverman

Pharmalittle: Canada OKs ALS drug still waiting FDA approval; WTO talks on Covid patent waiver are down to the wire

Pharmalot By Ed Silverman

Pharmalittle: FDA panel endorses Bluebird Bio gene therapy for rare disease; GSK touts RSV vaccine trial results

Smallpox Vaccination

Politics By Rachel Cohrs

How much medicine does the U.S. actually have to fight monkeypox?

Lab technician wearing blue gloves holding a reactive test for monkey pox.

Health By Helen Branswell and Andrew Joseph

‘Testing bottleneck’ for monkeypox puts hope of containment at risk, experts warn

Politics By Lev Facher

Francis Collins: Concern about independence of new moonshot science agency ARPA-H are ‘overblown’

First Opinion By Peter J. Pitts

Beyond baby formula: advancing best practices in FDA’s efforts to prevent shortages

Politics By Rachel Cohrs

How the Covid-19 pandemic prepared the White House to respond to monkeypox

Novartis

Pharmalot By Ed Silverman

Documents show problems at Novartis facility where cancer drug production was halted

JUNE Xavier Becerra

Politics By Rachel Cohrs

Biden administration won’t lower seniors’ Medicare premiums this year, despite changes to coverage of new Alzheimer’s drug

Aduhelm package

Politics By Lev Facher

Key Senate committee proposes a council to ensure FDA better coordinates on accelerated approvals

Politics By Nicholas Florko

The FDA says it’s in the dark about thousands of dietary supplement ingredients

pills

Pharmalot By Ed Silverman

European regulator suspends generic drugs after finding flawed studies

kids covid vaccine

Health By Matthew Herper

CDC recommends Covid boosters for kids ages 5 to 11 after advisory committee vote

Exclusive By Nicholas Florko

Senate FDA legislation will include dietary supplement, cosmetic reforms

Worldwide Covid-19 vaccinations

Pharmalot By Ed Silverman

National Institutes of Health licenses nearly a dozen Covid-19 technologies to a WHO program

Health Tech By Mario Aguilar

The FDA eased rules for mental health apps during the pandemic. Now companies are bracing for it to tighten the reins

Politics By Lev Facher

The panel was supposed to improve efficiency at the NIH. It hasn’t even met for 7 years

Barrier to meds

First Opinion By Brian Barnett

Flawed FDA safety requirements are hamstringing a highly effective treatment for severe schizophrenia

FDA

Pharmalot By Ed Silverman

FDA warns Miami University contract testing lab over falsified data, poor quality control